Radius Health Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health or view top-rated stocks.

5 equities research analysts have issued 1 year target prices for Radius Health's stock. Their RDUS stock forecasts range from $7.00 to $10.00. On average, they predict Radius Health's stock price to reach $8.60 in the next year. This suggests that the stock has a possible downside of 17.6%.
View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts.

Radius Health's stock was trading at $6.92 on January 1st, 2022. Since then, RDUS shares have increased by 50.9% and is now trading at $10.44.
View the best growth stocks for 2022 here.

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Radius Health.

Radius Health, Inc. (NASDAQ:RDUS) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.18. The biopharmaceutical company had revenue of $43.16 million for the quarter, compared to analysts' expectations of $51.42 million. During the same quarter in the previous year, the business earned ($0.34) earnings per share.
View Radius Health's earnings history.

Some companies that are related to Radius Health include Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), Arcus Biosciences (RCUS), OPKO Health (OPK), Lyell Immunopharma (LYEL), Amphastar Pharmaceuticals (AMPH), Xenon Pharmaceuticals (XENE), Xencor (XNCR), Dynavax Technologies (DVAX), Emergent BioSolutions (EBS), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN) and Cryoport (CYRX).
View all of RDUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bellevue Group AG (17.49%), State Street Corp (8.11%), Vanguard Group Inc. (7.65%), BlackRock Inc. (7.48%), Velan Capital Investment Management LP (2.99%) and UBS Group AG (2.83%). Company insiders that own Radius Health stock include Anthony Rosenberg, Growth N V Biotech, James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wellington Management Group LLP, UBS Group AG, State Street Corp, Bank of New York Mellon Corp, Walleye Capital LLC, Walleye Capital LLC, and Bank of America Corp DE.
View insider buying and selling activity for Radius Health or view top insider-selling stocks.

RDUS stock was bought by a variety of institutional investors in the last quarter, including Velan Capital Investment Management LP, Bellevue Group AG, Acadian Asset Management LLC, Eversept Partners LP, JPMorgan Chase & Co., Assenagon Asset Management S.A., BNP Paribas Arbitrage SA, and Pinz Capital Management LP. Company insiders that have bought Radius Health stock in the last two years include Rubric Capital Management Lp, and Target N V Biotech.
View insider buying and selling activity for Radius Health or or view top insider-buying stocks.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RDUS stock can currently be purchased for approximately $10.44.

Radius Health (NASDAQ:RDUS) has a market capitalization of $496.94 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70.18 million in net income (profit) each year or ($1.540010) on an earnings per share basis.

Radius Health employs 293 workers across the globe.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for Radius Health is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.